NervGen (NGEN) Stock Price Target Cut to $15 Due to Dilution

H.C. Wainwright has reduced the stock price target for NervGen Pharma (NGEN) to $15. This adjustment reflects concerns over share dilution affecting the company's market valuation. Investors may perceive this downward revision as a sign of potential challenges for NervGen in maintaining stock price stability. The decrease in the target price could impact investor confidence and trading volumes going forward.